April 2024

"I couldn't carry on taking a drug like that": A qualitative study of patient perspectives on side effects from rheumatology drugs

Journal Reference: Rheumatology 2024 Epub ahead of print

In the treatment of rheumatic and musculoskeletal diseases (RMDs), there is a need for feasible measures of patient-reported bother (impact on life and cumulative burden) from side effects and the benefit-harm-balance. Berthelsen et al. evaluated what with RMDs considered important to know about symptomatic side effects they may experience from a new prescription drug.

Keywords:

January 2022

Réduction de la douleur chez les patients atteints de polyarthrite rhumatoïde prenant des opioïdes : une analyse post hoc des essais de phase 3 du baricitinib

ACR Open Rheumatol. 2021. Epub ahead of print. doi: 10.1002/acr2.11380

This post hoc analysis shows that pain reduction was similar between opioid users and nonusers with baricitinib 2 mg and 4 mg, but not adalimumab.Use of opioids to treat RA-related pain has increased, yet long-term use has been associated with reduced efficacy and safety concerns. In addition, the misuse of opioids has resulted in a public health crisis in the United States and highlights the need for safe, effective nonaddictive alternatives for pain management. As such, Pope, et al. assessed p...

Keywords:

February 2021

La voie JAK/STAT : Un Regard sur la Douleur dans la Polyarthrite Rhumatoïde

Semin Arthritis Rheum. 2021 Feb;51(1):278-284

Many cytokines associated with RA pathogenesis and pain are affected directly or indirectly by the JAK/STAT pathway, therapeutic targeting may offer promise. Having better understanding of these mechanisms can help clinicians make treatment decisions that optimise the control of inflammation and pain. However, pain in patients with RA is complex and involves multiple driving mechanisms that may differentially occur over time in different people. Although one known constant is that nociceptive ac...

Keywords: